ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2020 Congress

Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Theme Navigation

  • ISTH 2020 Congress
    • Hemophilia and Rare Bleeding Disorders
      • Hemophilia - Clinical

Abstract Number: PB0972

“Best of Both Worlds”: Combination Treatment of Desmopressin and FVIII Concentrates in Hemophilia Patients Optimizes Therapy and Reduces Costs

L.G.R. Romano1, L.M. Schütte1, R.M. van Hest2, K. Meijer3, B.A.P. Laros-van Gorkom4, L. Nieuwenhuizen5, J. Eikenboom6, F.C.J.I. Moenen7, N. Uitslager8, M. Coppens9, M.H. Cnossen10, K. Fijnvandraat11,12, M.H.E. Driessens13, S. Polinder14, F.W.G. Leebeek1, R.A.A. Mahtôt2, M.J.H.A. Kruip1

Abstract Number: PB1058

Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIIIFc and Emicizumab after Failed First Line Therapy with High Dose ITI

I. Wieland1, K.-A. Lambeck1, D. Stichel2, A. Orlowski2, C. Königs2

Abstract Number: PB1041

3D Gait Analysis, Hemophilia Joint Health Score, Leg Muscle Laterality, and Biomarkers of Joint Damage: A Cross-sectional Comparative Assessment of Hemophilic Arthropathy

P. Putz1, S. Durstberger2, C. Kaufmann2, M. Klinger2, K. Widhalm2, J. Rejtö3, C. Male4, I. Pabinger3

Abstract Number: PB0905

A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting

D. Matino1, A. Iorio1, A. Keepanasseril1, F. Germini2, A.C. Birkegård3, A. Caillaud4, M. Carcao5, J. Hews-Girard6, E. Iserman7, P. James8, A. Lee9, C. Phua10, H. Sun11, J. Teitel12, M.-C. Poon13

Abstract Number: PB1075

A Descriptive Study of Physical Activity and Fitness Level Profiles of Nigerians with Haemophila

H. Okoye1, T. Nwagha1, N. Chigbo2, E. Anekwu3

Abstract Number: PB0889

A French Multicentre Prospective, Non-Interventional Study (B-SURE) Evaluating Real-World Usage and Effectiveness of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B: Baseline Data

H. Chambost1, B. Wibaut2, A. Borel Derlon3, S. Claeyssens4, S. Castet5, R. d'Oiron6,7, C. Negrier8, H. Andersson9, S. Bergenstråle9, C. Gandossi10, C. Martinez10

Abstract Number: PB1034

A Multicenter Open-label Single Arm Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Patients with Severe Hemophilia A under Prophylaxis Therapy

W. Liu1, X. Zhao2, F. Xue1, J. Sun3, X. Zeng4, F. Yang5, Z. Yu6, M. Xu7, W. Li8, W. Gu9, Y. Feng10, C. Zheng11, H. Bi12, R. Yang1

Abstract Number: PB0896

A Randomized Controlled Trial: Pharmacokinetic-Guided Dosing of Factor VIII Concentrate Versus Standard Replacement Therapy in Perioperative Hemophilia A Patients (OPTI-CLOT Trial)

I. van Moort1, T. Preijers2, L. Bukkems2, H. Hazendonk1, B. Laros-van Gorkom3, E. Beckers4, L. Nieuwenhuizen5, F. van der Meer6, P. Ypma7, M. Coppens8, K. Fijnvandraat9,10, R. Schutgens11, K. Meijer12, F. Leebeek13, R. Mathot2, M. Cnossen1, OPTI-CLOT Study Group

Abstract Number: PB0957

A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Persons with Hemophilia A in the Asia-Pacific region (HAVEN 5)

S. Wang1, X. Zhao2, X. Wang3, J. Sun4, A. Chuansumrit5, J. Zhou6, L. Li7, W. Hsu7, J. Xu7, P. Barrington8, R. Yang9

Abstract Number: PB0875

A Real-World Qualitative Analysis of the Burden of Hemophilia B and Patient Experiences with Prophylactic Nonacog Beta Pegol

C. Phua1, M. Faurby2, V. Macdonald3, J. Lambert4, J. Teitel5

Abstract Number: PB1053

A Simplified Health Education Program Improves Knowledge and Practices of Home Treatment in Hemophilia A Adolescents in a Developing Country

T. Hassan1, M. Hesham1, A. El Dakhakhny2, M. Zakaria1, M. Hanfy2

Abstract Number: PB0953

A Single Center Data on Extended Half-Life Recombinant Factor VIII (FVIII:Fc) in Patients with Hemophilia A

S. Braham1, R. Gualtierotti2, E. Biguzzi1, S.M. Siboni1, E. Bregani3, M. Boscarino4, M.E. Mancuso1, F. Peyvandi1,2

Abstract Number: PB1062

A Snapshot of a Prospective, Non-interventional Study to Evaluate Routine Practice Prophylactic Treatment Schedules – NIS-Previq

S. Halimeh1, W. Behnisch2, C. Escuriola-Ettingshausen3, J. Feddern4, A. Huth-Kühne5, J. Oldenburg6, U. Scholz7, S. Seeger4, S. Wenning5, R. Klamroth8

Abstract Number: PB0954

Abdominal Catastrophe in Hemophilic Patients: Towards Wise Decision Making

M. Abdelkader Morad, M. Elkholy, M. Mattar, M. Hasab Allah, A. Ayad, S. Habib, G. Nashed

Abstract Number: PB0962

Adverse Event Reporting in Haemophilia A Patients with and without Inhibitors Treated with Emicizumab: A Report from the Co-morbidity Working Party of the UK Haemophilia Centres Doctors´ Organisation (UKHCDO)

C. Wall1, G. Hall2, P. Collins3, M. Makris4, S. Shapiro5, R. Liesner6, C. Harrison4, R. Maclean4, S. Mangles7, G. Benson8, G. Evans9, P. Sartain10, C. Hay11, UK National Haemophilia Database

Abstract Number: OC 09.3

An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study

F. Nissen1, T. Burke2, S. Asghar2, E. Ferri Grazzi2, A. Shang1, F. Castro1, M. Aizenas1, O. Meier1, J. O'Hara2,3

Abstract Number: PB1055

ASCVD Risk Score among Haemophilia Patients: Time to Formally Evaluate Cardiovascular Risk in People with Haemophilia

R. Camelo1,2,3, B.P. Duarte2, M.C.B. Moura2, N.C.M. Costa2, I.M. Costa2, C.G.P. Roncal2, A.M. Vanderlei2, T.M.R. Guimaraes2, C. Caram Deelder3,4, S.C. Gouw3, S.M. Rezende1, J.G. van der Bom3,4

Abstract Number: PB0897

Assessing the Bleeding Phenotype in Non-Severe hemophilia by use of the ISTH Bleeding Assessment Tool (BAT)

F.R. Kloosterman1, A. Zwagemaker1, C.N. Bagot2, E.A.M. Beckers3, J.G. van der Bom4, P. Collins5, M.H. Cnossen6, M. Coppens7, S.C. Gouw1,4, B.A.P. Laros-van Gorkum8, S. Mangles9, F.J.M. van der Meer10, K. Meijer11, L. Nieuwenhuizen12, R. Schutgens13, K. Fijnvandraat1

Abstract Number: PB1012

Association Between Aging and Health Status in Persons Leaving with Hemophilia and Controls Without a Bleeding Disorder – Insights from the PROBE Study

F. Germini1,2, S. O'Callaghan3, C. Chai-Adisaksopha2,4, R. Curtis5, N. Frick6, M. Nichol7, D. Noone8,9, B. O'Mahony10, D. Page11, J. Stonebraker12, M. Skinner1,13, A. Iorio1,14, PROBE investigators

Abstract Number: PB1056

Association between Platelet Glycoprotein Common SNVs and Bleeding Severity in Haemophilia Patients

L. Bury1, G. Piroli1, H. Kuchi Bhotla1, M. Borghi1, E. Cesari1, E. Falcinelli1, R. De Cristofaro2,3, B. Zieger4, P. Gresele1

  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

« View all themes from the ISTH 2020 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2021 John Wiley & Sons, Inc. All Rights Reserved.
Wiley
This site uses cookies: Find out more.